CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance
Modern Rheumatology · 2024
DOI: 10.1093/mr/road077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Shigeru Tanaka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Abatacept, Arthritis, Rheumatoid, Receptors, CCR4, Th17 Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objectives
Predicting the efficacy of biological disease–modifying antirheumatic drugs is challenging. In this study, we aimed to explore markers that predict the efficacy of abatacept in rheumatoid arthritis (RA) patients.
Methods
Thirty RA patients receiving abatacept were recruited, and peripheral blood mononuclear cells from the participants were subjected to DNA microarray analysis. The expression of CC chemokine receptor 4 (CCR4), which was selected by the result of DNA microarray, was determined by flow cytometry in 16 newly diagnosed treatment-naïve RA patients. CCR4 expression on each helper T-cell subset was also measured.
Results
CCR4 was upregulated in the abatacept responder. The expression levels of CCR4 were significantly correlated with the improvement of the Clinical Disease Activity Index. CCR4 expression was predominantly observed in CD4+ T cells in peripheral blood mononuclear cells. The percentage of CCR4-expressing CD4+ T cells was significantly higher in RA patients than in healthy individuals. Interestingly, Th17 and Treg cells expressed high levels of CCR4 compared to non-Th17-related helper T cells.
Conclusions
CCR4 is a Th17- and Treg-related gene, and the high CCR4 expression in peripheral blood samples may predict the efficacy of abatacept in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Graduate School of Medicine, Institute for Advanced Academic Research, Chiba, Japan.
- Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba, Japan.
ORCID-Profile: Shigeru Tanaka
Zitieren
APA
Tanaka, S., Etori, K., Hattori, K., Tamura, J., Ikeda, K., Kageyama, T., Meguro, K., Iwamoto, T., Iwata, A., Furuta, S., Suto, A., Suzuki, K., & Nakajima, H. (2024). CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance. Modern Rheumatology. https://doi.org/10.1093/mr/road077
Vancouver
Tanaka S, Etori K, Hattori K, Tamura J, Ikeda K, Kageyama T, et al. CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance. Modern Rheumatology. 2024. doi:10.1093/mr/road077
BibTeX
@article{Tanaka2024,
author = {Tanaka, Shigeru and Etori, Keishi and Hattori, Koto and Tamura, Jun and Ikeda, Kei and Kageyama, Takahiro and Meguro, Kazuyuki and Iwamoto, Taro and Iwata, Arifumi and Furuta, Shunsuke and Suto, Akira and Suzuki, Kotaro and Nakajima, Hiroshi},
title = {CCR4 predicts the efficacy of abatacept in rheumatoid arthritis patients through the estimation of Th17 and Treg cell abundance},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/road077}
}
EUVIMED